Limits...
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH - Br. J. Cancer (2009)

Bottom Line: P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu).Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome.Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

ABSTRACT

Background: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.

Methods: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.

Results: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.

Conclusions: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies.

Show MeSH

Related in: MedlinePlus

Search strategy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2713689&req=5

fig1: Search strategy.

Mentions: Two researchers (PdG and APGC) independently examined abstracts of articles (n=614) to decide whether full-text articles should be obtained (Figure 1). Cases of disagreement were resolved by discussing the title and abstract. Full-text articles (n=216) were examined and excluded if a more detailed examination revealed that they did not meet the inclusion criteria. The sample size of included studies did not differ from the sample size of excluded studies (data not shown). Where applicable, we adhered to the QUORUM criteria for improving the quality of reporting of meta-analyses (Moher et al, 1999).


Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH - Br. J. Cancer (2009)

Search strategy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2713689&req=5

fig1: Search strategy.
Mentions: Two researchers (PdG and APGC) independently examined abstracts of articles (n=614) to decide whether full-text articles should be obtained (Figure 1). Cases of disagreement were resolved by discussing the title and abstract. Full-text articles (n=216) were examined and excluded if a more detailed examination revealed that they did not meet the inclusion criteria. The sample size of included studies did not differ from the sample size of excluded studies (data not shown). Where applicable, we adhered to the QUORUM criteria for improving the quality of reporting of meta-analyses (Moher et al, 1999).

Bottom Line: P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu).Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome.Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynaecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

ABSTRACT

Background: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.

Methods: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.

Results: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.

Conclusions: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies.

Show MeSH
Related in: MedlinePlus